Current Chemotherapy Use in Neuroendocrine Tumors

• Autores: David L. Chan, Simron Singh
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 47, Nº. 3, 2018 (Ejemplar dedicado a: Innovations in the Management of Neuroendocrine Tumors), págs. 603-614
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The incidence of neuroendocrine tumors (NETs) has increased over the past 30 years, and they are the second most prevalent gastrointestinal tumor behind colorectal can- cer. NETs are heterogeneous neoplasms that most commonly arise from the gastro- intestinal tract, pancreas, and lung. Their biological behavior can vary widely, and for this reason characterization of NETs relies as much on their histologic grading as the primary site of disease. Grade 1 (G1) NETs may display extremely indolent behavior, whereas grade 3 (G3) NETs may grow over a matter of weeks and require urgent treat- ment. Gastrointestinal tumors are graded using the World Health Organization (WHO) 2010 system, using a combination of the mitotic count and Ki-67 index. The WHO